New Research Links Hypoglycemia to Worsening Diabetic Retinopathy
Recent studies indicate that low blood sugar levels, known as hypoglycemia, may aggravate diabetic retinopathy by compromising the blood-retinal barrier. In diabetic mice, episodes of low blood sugar elevated levels of hypoxia-inducible factor (HIF), a protein associated with abnormal blood vessel development and leakage.
Interestingly, an experimental drug that inhibits HIF was able to prevent this damage, indicating a potential new avenue for therapy. The findings shed light on why some patients with consistently tight glucose control or fluctuating sugar levels might see their eye condition worsen.
Key Insights:
- HIF Activation and Blood Sugar: Low glucose levels led to increased HIF in diabetic mice, which triggered leakage of retinal blood vessels.
- Impact on Vision: Disruption of the blood-retinal barrier driven by HIF could worsen diabetic retinopathy.
- Potential Treatment: The drug 32-134D, which blocks HIF, showed promise by reducing retinal leakage.
In a study funded by the National Institutes of Health and conducted at Johns Hopkins Medicine’s Wilmer Eye Institute, researchers explored how hypoglycemia affects the blood-retinal barrier, an essential boundary that manages nutrient and waste exchange within the retina.
This research specifically delved into the connection between diabetic retinopathy and episodes of low blood sugar in patients. This condition is a serious complication arising from both type 1 and type 2 diabetes and can result in irreversible vision loss if not treated properly.
The study, published in Science Translational Medicine, outlines how HIF accumulates in certain retinal cells during low blood sugar phases. Previous knowledge indicated HIF’s involvement in conditions like diabetic retinopathy. It can instigate a cascade of reactions leading to excess protein production that causes overgrowth and leakage in retinal blood vessels. Now, researchers have pinpointed how HIF contributes to the breakdown of the blood-retinal barrier during these hypoglycemic episodes.
In their experiments, they induced low blood sugar in both diabetic and non-diabetic mice. The results revealed that diabetic mice had increased HIF levels during hypoglycemia, leading to barrier breakdown and blood vessel leakage, a response not seen in non-diabetic mice.
This breakdown plays a significant role in the permanent damage seen in the retinas of those with diabetic retinopathy. To investigate further, the researchers tested an experimental drug called 32-134D that inhibits HIF. When given before inducing low blood sugar in diabetic mice, 32-134D significantly reduced HIF, preventing the cascade that leads to barrier breakdown.
“This research helps clarify why diabetes patients who begin strict glucose management or experience drastic swings in blood sugar may find their eye disease worsening,” said Dr. Akrit Sodhi, a key researcher. “Our findings stress the potential efficacy of HIF-targeted therapies in treating or preventing diabetic retinopathy.”
Looking ahead, researchers are planning further studies on HIF and the blood-retinal barrier breakdown and aim to assess the effectiveness of 32-134D in clinical settings for patients suffering from diabetic retinopathy.
